# üìö H∆∞·ªõng d·∫´n Chi ti·∫øt 20 Lo·∫°i Quan h·ªá Y t·∫ø

## üîÑ So s√°nh: 10 ‚Üí 20 Lo·∫°i Quan h·ªá

### Tr∆∞·ªõc (10 lo·∫°i):
```
1. CAUSES
2. HAS_SYMPTOM
3. INDICATES
4. TREATS
5. REQUIRES_TEST
6. CONTRAINDICATED
7. INCREASES_RISK
8. COMPLICATION_OF
9. ASSOCIATED_WITH
10. WORSENS
```

### Sau (20 lo·∫°i - +10 lo·∫°i M·ªöI):
```
‚úÖ C≈©:
1. CAUSES
2. HAS_SYMPTOM
3. INDICATES
4. TREATS
5. REQUIRES_TEST
6. CONTRAINDICATED
7. INCREASES_RISK
8. COMPLICATION_OF
9. ASSOCIATED_WITH
10. WORSENS

üÜï M·ªõi:
11. MANAGE_WITH ‚≠ê
12. DOSAGE_ADJUSTMENT ‚≠ê
13. CONTRAINDICATED_WITH ‚≠ê
14. MONITORING_REQUIRED ‚≠ê
15. PREVENTS ‚≠ê
16. METABOLIZED_BY ‚≠ê
17. SIDE_EFFECT_OF ‚≠ê
18. INTERACTION_WITH ‚≠ê
19. STAGES ‚≠ê
20. RISK_STRATIFICATION ‚≠ê
```

---

## üìñ Gi·∫£i th√≠ch Chi ti·∫øt T·ª´ng Lo·∫°i

### GROUP 1: DISEASE - SYMPTOM/OUTCOME (3 lo·∫°i)

#### 1Ô∏è‚É£ HAS_SYMPTOM
- **ƒê·ªãnh nghƒ©a**: B·ªánh c√≥ tri·ªáu ch·ª©ng
- **H∆∞·ªõng**: B·ªánh ‚Üí Tri·ªáu ch·ª©ng
- **V√≠ d·ª•**:
  - B·ªánh th·∫≠n m·∫°n ‚Üí Ph√π ch√¢n
  - ƒê√°i th√°o ƒë∆∞·ªùng ‚Üí Kh√°t n∆∞·ªõc
  - Huy·∫øt √°p cao ‚Üí ƒêau ƒë·∫ßu
- **Lu√¥n tr√≠ch**: Khi vƒÉn b·∫£n n√≥i b·ªánh g√¢y ra tri·ªáu ch·ª©ng
- **Confidence**: 8-10 (r√µ r√†ng) ho·∫∑c 5-6 (g·ª£i √Ω)

#### 2Ô∏è‚É£ COMPLICATION_OF
- **ƒê·ªãnh nghƒ©a**: Bi·∫øn ch·ª©ng c·ªßa b·ªánh (h·ªá qu·∫£ n·∫∑ng h∆°n)
- **H∆∞·ªõng**: Bi·∫øn ch·ª©ng ‚Üí B·ªánh g·ªëc
- **V√≠ d·ª•**:
  - TƒÉng kali m√°u ‚Üê B·ªánh th·∫≠n
  - Lo·∫°n nh·ªãp ‚Üê B·ªánh th·∫≠n
  - Suy tim ‚Üê Huy·∫øt √°p cao (m·∫°n t√≠nh)
- **Kh√°c v·ªõi HAS_SYMPTOM**: Complication = tri·ªáu ch·ª©ng/b·ªánh n·∫∑ng h∆°n
- **Confidence**: 8-10

#### 3Ô∏è‚É£ ASSOCIATED_WITH
- **ƒê·ªãnh nghƒ©a**: Li√™n quan v·ªõi nhau (kh√¥ng r√µ nh√¢n qu·∫£)
- **H∆∞·ªõng**: Hai chi·ªÅu (A ‚Üî B)
- **V√≠ d·ª•**:
  - Ti·ªÉu ƒë∆∞·ªùng ‚Üî B√©o ph√¨
  - B·ªánh th·∫≠n ‚Üî Thi·∫øu m√°u
  - Huy·∫øt √°p cao ‚Üî B·ªánh tim
- **Khi d√πng**: Khi ch·ªâ n√≥i "li√™n quan" kh√¥ng r√µ g√¢y-g√¢y
- **Confidence**: 5-8

---

### GROUP 2: CAUSATION & RISK (4 lo·∫°i)

#### 4Ô∏è‚É£ CAUSES
- **ƒê·ªãnh nghƒ©a**: G√¢y ra tr·ª±c ti·∫øp (nh√¢n qu·∫£ r√µ r√†ng)
- **H∆∞·ªõng**: Nguy√™n nh√¢n ‚Üí B·ªánh/tri·ªáu ch·ª©ng
- **V√≠ d·ª•**:
  - Ti·ªÉu ƒë∆∞·ªùng ‚Üí B·ªánh th·∫≠n m·∫°n
  - Huy·∫øt √°p cao ‚Üí B·ªánh th·∫≠n m·∫°n
  - H√∫t thu·ªëc ‚Üí Ung th∆∞ ph·ªïi
- **Confidence**: 9-10 (r√µ nh·∫•t)
- **Kh√°c v·ªõi INCREASES_RISK**: CAUSES = ch·∫Øc ch·∫Øn, INCREASES_RISK = tƒÉng nguy c∆°

#### 5Ô∏è‚É£ INCREASES_RISK
- **ƒê·ªãnh nghƒ©a**: TƒÉng nguy c∆° b·ªánh (y·∫øu t·ªë nguy c∆°)
- **H∆∞·ªõng**: Y·∫øu t·ªë ‚Üí B·ªánh
- **V√≠ d·ª•**:
  - H√∫t thu·ªëc ‚Üí ‚Üë nguy c∆° ung th∆∞
  - GFR < 60 ‚Üí ‚Üë nguy c∆° ung th∆∞ th·∫≠n
  - B√©o ph√¨ ‚Üí ‚Üë nguy c∆° ti·ªÉu ƒë∆∞·ªùng
- **Confidence**: 7-9
- **Note**: Kh√¥ng ch·∫Øc ch·∫Øn 100%, nh∆∞ng tƒÉng x√°c su·∫•t

#### 6Ô∏è‚É£ WORSENS
- **ƒê·ªãnh nghƒ©a**: L√†m n·∫∑ng t√¨nh tr·∫°ng hi·ªán c√≥
- **H∆∞·ªõng**: Y·∫øu t·ªë ‚Üí B·ªánh (l√†m n·∫∑ng)
- **V√≠ d·ª•**:
  - TƒÉng kali ‚Üí Lo·∫°n nh·ªãp tim
  - C√°c nhi·ªÖm khu·∫©n ‚Üí Suy th·∫≠n (n·∫∑ng h∆°n)
  - Kh√¥ng tu√¢n th·ªß ‚Üí B·ªánh th·∫≠n (ti·∫øn tri·ªÉn nhanh)
- **Confidence**: 7-9

#### 7Ô∏è‚É£ PREVENTS
- **ƒê·ªãnh nghƒ©a**: Ph√≤ng ng·ª´a b·ªánh
- **H∆∞·ªõng**: Bi·ªán ph√°p ‚Üí B·ªánh
- **V√≠ d·ª•**:
  - Vaccin c√∫m ‚Üí Ph√≤ng Pneumonia
  - Thay th·∫≠n ‚Üí Ph√≤ng t·ª≠ vong do suy th·∫≠n
  - Thu·ªëc h·∫° cholesterol ‚Üí Ph√≤ng suy tim
- **Confidence**: 7-10 (t√πy ch·ª©ng c·ª©)

---

### GROUP 3: DIAGNOSIS & MONITORING (5 lo·∫°i)

#### 8Ô∏è‚É£ INDICATES
- **ƒê·ªãnh nghƒ©a**: Ch·ªâ ƒë·ªãnh ch·∫©n ƒëo√°n b·ªánh
- **H∆∞·ªõng**: Tri·ªáu ch·ª©ng/Test ‚Üí B·ªánh
- **V√≠ d·ª•**:
  - GFR < 15 ‚Üí B·ªánh th·∫≠n giai ƒëo·∫°n 5
  - Protein ni·ªáu > 3g/24h ‚Üí H·ªôi ch·ª©ng th·∫≠n h∆∞
  - Ho > 3 tu·∫ßn ‚Üí Lao
- **Confidence**: 8-10

#### 9Ô∏è‚É£ REQUIRES_TEST
- **ƒê·ªãnh nghƒ©a**: B·ªánh c·∫ßn ki·ªÉm tra gi√°m s√°t
- **H∆∞·ªõng**: B·ªánh ‚Üí Test
- **V√≠ d·ª•**:
  - B·ªánh th·∫≠n ‚Üí X√©t nghi·ªám GFR
  - Ti·ªÉu ƒë∆∞·ªùng ‚Üí X√©t nghi·ªám glucose
  - Huy·∫øt √°p cao ‚Üí ƒêo huy·∫øt √°p h√†ng ng√†y
- **Confidence**: 8-9

#### üîü MONITORING_REQUIRED
- **ƒê·ªãnh nghƒ©a**: C·∫ßn theo d√µi li√™n t·ª•c (k√®m t·∫ßn su·∫•t)
- **H∆∞·ªõng**: T√¨nh tr·∫°ng ‚Üí Test (li√™n t·ª•c)
- **V√≠ d·ª•**:
  - B·ªánh th·∫≠n giai ƒëo·∫°n 4 ‚Üí GFR (3 th√°ng/l·∫ßn)
  - Tr√™n EPO ‚Üí Hemoglobin (h√†ng th√°ng)
  - Tr√™n Warfarin ‚Üí INR (h√†ng th√°ng)
- **Evidence**: N√™n bao g·ªìm t·∫ßn su·∫•t
- **Confidence**: 8-9

#### 1Ô∏è‚É£1Ô∏è‚É£ STAGES (M·ªõi)
- **ƒê·ªãnh nghƒ©a**: Giai ƒëo·∫°n c·ªßa b·ªánh
- **H∆∞·ªõng**: Giai ƒëo·∫°n c·ª• th·ªÉ ‚Üí B·ªánh chung
- **V√≠ d·ª•**:
  - B·ªánh th·∫≠n m·∫°n giai ƒëo·∫°n 5 ‚Üí Stage of: B·ªánh th·∫≠n m·∫°n
  - CKD giai ƒëo·∫°n 3b ‚Üí Stage of: CKD
  - CHF NYHA IV ‚Üí Stage of: Suy tim
- **Confidence**: 9-10

#### 1Ô∏è‚É£2Ô∏è‚É£ RISK_STRATIFICATION (M·ªõi)
- **ƒê·ªãnh nghƒ©a**: Ph√¢n t·∫ßng nguy c∆° (k·∫øt h·ª£p nhi·ªÅu y·∫øu t·ªë)
- **H∆∞·ªõng**: Y·∫øu t·ªë ‚Üí M·ª©c nguy c∆°
- **V√≠ d·ª•**:
  - GFR 15-29 + Protein ni·ªáu ‚Üë ‚Üí HIGH RISK progression
  - eGFR < 15 + Reanin ‚Üë ‚Üí HIGH RISK ESRD
  - Triple positive ‚Üí HIGH RISK t·ª≠ vong
- **Note**: Th∆∞·ªùng d√πng cho prognosis
- **Confidence**: 7-9

---

### GROUP 4: TREATMENT (5 lo·∫°i)

#### 1Ô∏è‚É£3Ô∏è‚É£ TREATS
- **ƒê·ªãnh nghƒ©a**: Thu·ªëc/li·ªáu ph√°p ƒëi·ªÅu tr·ªã b·ªánh
- **H∆∞·ªõng**: Thu·ªëc ‚Üí B·ªánh
- **V√≠ d·ª•**:
  - Erythropoietin ‚Üí Thi·∫øu m√°u
  - Lisinopril ‚Üí B·ªánh th·∫≠n (ch·∫≠m ti·∫øn tri·ªÉn)
  - Thay th·∫≠n ‚Üí Suy th·∫≠n giai ƒëo·∫°n 5
- **Confidence**: 8-10

#### 1Ô∏è‚É£4Ô∏è‚É£ MANAGE_WITH (M·ªõi ‚≠ê)
- **ƒê·ªãnh nghƒ©a**: Qu·∫£n l√Ω/ƒëi·ªÅu tr·ªã k·∫øt h·ª£p v·ªõi c√°c bi·ªán ph√°p kh√°c
- **H∆∞·ªõng**: B·ªánh/Tri·ªáu ch·ª©ng ‚Üí K·∫øt h·ª£p thu·ªëc/li·ªáu ph√°p
- **V√≠ d·ª•**:
  - Thi·∫øu m√°u do suy th·∫≠n ‚Üí MANAGE_WITH: EPO + S·∫Øt + Folic acid
  - Huy·∫øt √°p cao ‚Üí MANAGE_WITH: ACE-I + Calcium blocker
  - B·ªánh th·∫≠n ‚Üí MANAGE_WITH: Gi√∫p ƒë·ª° to√†n di·ªán + Ch·∫ø ƒë·ªô ƒÉn
- **Kh√°c v·ªõi TREATS**: 
  - TREATS = m·ªôt thu·ªëc ƒëi·ªÅu tr·ªã
  - MANAGE_WITH = chi·∫øn l∆∞·ª£c ƒëi·ªÅu tr·ªã to√†n di·ªán
- **Confidence**: 7-9

#### 1Ô∏è‚É£5Ô∏è‚É£ SIDE_EFFECT_OF (M·ªõi ‚≠ê)
- **ƒê·ªãnh nghƒ©a**: T√°c d·ª•ng ph·ª• c·ªßa thu·ªëc
- **H∆∞·ªõng**: T√°c d·ª•ng ph·ª• ‚Üê Thu·ªëc
- **V√≠ d·ª•**:
  - Ho kh√¥ ‚Üê Lisinopril (ACE-I)
  - TƒÉng kali ‚Üê ACE-I/ARB
  - Ph√π m·∫∑t ‚Üê Amlodipine
- **Note**: T·ªáp n√†y QUAN TR·ªåNG cho ƒë·ªôc t√≠nh th·∫øp
- **Confidence**: 8-10

#### 1Ô∏è‚É£6Ô∏è‚É£ DOSAGE_ADJUSTMENT (M·ªõi ‚≠ê)
- **ƒê·ªãnh nghƒ©a**: C·∫ßn ƒëi·ªÅu ch·ªânh li·ªÅu theo t√¨nh tr·∫°ng
- **H∆∞·ªõng**: Y·∫øu t·ªë ‚Üí Thu·ªëc (ƒëi·ªÅu ch·ªânh li·ªÅu)
- **V√≠ d·ª•**:
  - GFR < 30 ‚Üí Gentamicin (gi·∫£m 50% li·ªÅu)
  - CrCl < 50 ‚Üí Metformin (tr√°nh/gi·∫£m li·ªÅu)
  - Tu·ªïi > 70 ‚Üí ACE-I (b·∫Øt ƒë·∫ßu li·ªÅu th·∫•p)
- **Evidence**: N√™n bao g·ªìm % ƒëi·ªÅu ch·ªânh ho·∫∑c khuy·∫øn c√°o
- **Confidence**: 8-10 (khi r√µ ch·ªâ ƒë·ªãnh)

#### 1Ô∏è‚É£7Ô∏è‚É£ CONTRAINDICATED
- **ƒê·ªãnh nghƒ©a**: Ch·ªëng ch·ªâ ƒë·ªãnh = KH√îNG d√πng danhthu·ªëc
- **H∆∞·ªõng**: T√¨nh tr·∫°ng ‚Üí Thu·ªëc (tr√°nh)
- **V√≠ d·ª•**:
  - Suy th·∫≠n n·∫∑ng ‚Üí Metformin (CONTRAINDICATED)
  - R·ªëi lo·∫°n kali ‚Üí ACE-I (CONTRAINDICATED)
  - Hemoglobin > 12 ‚Üí EPO (CONTRAINDICATED)
- **Confidence**: 9-10 (nghi√™m tr·ªçng)

---

### GROUP 5: DRUG-DRUG INTERACTIONS (3 lo·∫°i)

#### 1Ô∏è‚É£8Ô∏è‚É£ CONTRAINDICATED_WITH (M·ªõi ‚≠ê)
- **ƒê·ªãnh nghƒ©a**: Ch·ªëng ch·ªâ ƒë·ªãnh k·∫øt h·ª£p (thu·ªëc-thu·ªëc)
- **H∆∞·ªõng**: Thu·ªëc A ‚Üî Thu·ªëc B (tr√°nh k·∫øt h·ª£p)
- **V√≠ d·ª•**:
  - ACE-I ‚Üî ARB (CONTRAINDICATED_WITH)
  - Warfarin ‚Üî Aspirin (m·∫°nh) (CONTRAINDICATED_WITH)
  - Simvastatin ‚Üî Erythromycin (CONTRAINDICATED_WITH)
- **Evidence**: N√™n gi·∫£i th√≠ch l√Ω do
- **Confidence**: 8-10

#### 1Ô∏è‚É£9Ô∏è‚É£ INTERACTION_WITH (M·ªõi ‚≠ê)
- **ƒê·ªãnh nghƒ©a**: T∆∞∆°ng t√°c (h·ªá qu·∫£ c·ª• th·ªÉ)
- **H∆∞·ªõng**: Thu·ªëc A + Thu·ªëc B ‚Üí H·ªá qu·∫£
- **V√≠ d·ª•**:
  - Simvastatin + Erythromycin ‚Üí ‚Üë Rhabdomyolysis
  - Warfarin + NSAIDs ‚Üí ‚Üë Ch·∫£y m√°u
  - Methotrexate + NSAIDs ‚Üí ‚Üë T·ªïn th∆∞∆°ng th·∫≠n
- **Kh√°c v·ªõi CONTRAINDICATED_WITH**: 
  - CONTRAINDICATED = tr√°nh ho√†n to√†n
  - INTERACTION = h·ªá qu·∫£ c·ª• th·ªÉ, c√≥ th·ªÉ d√πng c·∫©n th·∫≠n
- **Confidence**: 7-9

#### 2Ô∏è‚É£0Ô∏è‚É£ METABOLIZED_BY (M·ªõi ‚≠ê)
- **ƒê·ªãnh nghƒ©a**: ƒê∆∞·ª£c chuy·ªÉn h√≥a b·ªüi enzyme
- **H∆∞·ªõng**: Thu·ªëc ‚Üí Enzyme (CYP450, Œ∫.v.)
- **V√≠ d·ª•**:
  - Warfarin ‚Üí Metabolized by: CYP2C9
  - Simvastatin ‚Üí Metabolized by: CYP3A4
  - Clopidogrel ‚Üí Metabolized by: CYP2C19
- **√ù nghƒ©a**: ƒê·ªÉ d·ª± b√°o t∆∞∆°ng t√°c
- **Confidence**: 9-10

---

## üí° H·ªôi ch·ª©ng Y t·∫ø To√†n di·ªán (V√≠ d·ª•)

C√πng m·ªôt ca b·ªánh, t·∫•t c·∫£ 20 quan h·ªá:

**T√¨nh hu·ªëng**: "B·ªánh nh√¢n n·ªØ 65 tu·ªïi, CKD giai ƒëo·∫°n 5 (GFR=12) v·ªõi ti·ªÉu ƒë∆∞·ªùng type 2, thi·∫øu m√°u (Hb=8), ƒë∆∞·ª£c ƒëi·ªÅu tr·ªã b·∫±ng EPO 4000 unit/week, Lisinopril, Metformin."

```
Entities: 
- B·ªánh th·∫≠n m·∫°n giai ƒëo·∫°n 5 (DISEASE)
- ƒê√°i th√°o ƒë∆∞·ªùng type 2 (DISEASE)
- Thi·∫øu m√°u (DISEASE)
- GFR=12 (LAB_VALUE)
- Hb=8 (LAB_VALUE)
- EPO 4000 unit/week (DRUG)
- Lisinopril (DRUG)
- Metformin (DRUG)

Relations:
 1Ô∏è‚É£ CAUSES: ƒê√°i th√°o ƒë∆∞·ªùng ‚Üí B·ªánh th·∫≠n (g√¢y ra tr·ª±c ti·∫øp)
 2Ô∏è‚É£ CAUSES: Huy·∫øt √°p cao ‚Üí B·ªánh th·∫≠n
 3Ô∏è‚É£ HAS_SYMPTOM: B·ªánh th·∫≠n ‚Üí Ph√π ch√¢n
 4Ô∏è‚É£ COMPLICATION_OF: Thi·∫øu m√°u ‚Üê B·ªánh th·∫≠n
 5Ô∏è‚É£ INDICATES: GFR=12 ‚Üí B·ªánh th·∫≠n giai ƒëo·∫°n 5
 6Ô∏è‚É£ REQUIRES_TEST: B·ªánh th·∫≠n ‚Üí X√©t nghi·ªám GFR
 7Ô∏è‚É£ MONITORING_REQUIRED: Thi·∫øu m√°u ‚Üí Hemoglobin (h√†ng th√°ng)
 8Ô∏è‚É£ STAGES: CKD giai ƒëo·∫°n 5 ‚Üí Stage of: B·ªánh th·∫≠n m·∫°n
 9Ô∏è‚É£ RISK_STRATIFICATION: GFR=12 + Protein‚Üë ‚Üí HIGH RISK ESRD
üîü TREATS: EPO ‚Üí Thi·∫øu m√°u
1Ô∏è‚É£1Ô∏è‚É£ MANAGE_WITH: Thi·∫øu m√°u ‚Üí EPO + S·∫Øt + Folic acid
1Ô∏è‚É£2Ô∏è‚É£ SIDE_EFFECT_OF: Ho kh√¥ ‚Üê Lisinopril
1Ô∏è‚É£3Ô∏è‚É£ DOSAGE_ADJUSTMENT: GFR < 30 ‚Üí Metformin (gi·∫£m li·ªÅu 50%)
1Ô∏è‚É£4Ô∏è‚É£ CONTRAINDICATED: GFR=12 ‚Üí Metformin (tr√°nh)
1Ô∏è‚É£5Ô∏è‚É£ CONTRAINDICATED_WITH: ACE-I ‚Üî ARB (n·∫øu d√πng c·∫£ 2)
1Ô∏è‚É£6Ô∏è‚É£ INTERACTION_WITH: Metformin + NSAID ‚Üí ‚Üë Acid lactic
1Ô∏è‚É£7Ô∏è‚É£ METABOLIZED_BY: Lisinopril ‚Üí Kidney (b√†i ti·∫øt)
1Ô∏è‚É£8Ô∏è‚É£ PREVENTS: Thay th·∫≠n ‚Üí Ph√≤ng t·ª≠ vong
1Ô∏è‚É£9Ô∏è‚É£ ASSOCIATED_WITH: CKD ‚Üî TƒÉng huy·∫øt √°p
2Ô∏è‚É£0Ô∏è‚É£ WORSENS: Kh√¥ng tu√¢n th·ªß ‚Üí CKD (ti·∫øn tri·ªÉn nhanh)
```

---

## ‚úÖ Checklist: C√°c quan h·ªá n√™n tr√≠ch

- [ ] **CAUSES** - Lu√¥n tr√≠ch n·∫øu n√≥i g√¢y b·ªánh
- [ ] **HAS_SYMPTOM** - Lu√¥n tr√≠ch n·∫øu n√≥i tri·ªáu ch·ª©ng
- [ ] **TREATS** - Lu√¥n tr√≠ch n·∫øu n√≥i ƒëi·ªÅu tr·ªã
- [ ] **INDICATES** - Lu√¥n tr√≠ch n·∫øu n√≥i ch·∫©n ƒëo√°n
- [ ] **CONTRAINDICATED** - Lu√¥n tr√≠ch n·∫øu n√≥i ch·ªëng ch·ªâ ƒë·ªãnh
- [ ] **SIDE_EFFECT_OF** - Lu√¥n tr√≠ch n·∫øu n√≥i t√°c d·ª•ng ph·ª•
- [ ] **DOSAGE_ADJUSTMENT** - Lu√¥n tr√≠ch n·∫øu n√≥i ƒëi·ªÅu ch·ªânh li·ªÅu
- [ ] **MONITORING_REQUIRED** - Tr√≠ch n·∫øu n√≥i theo d√µi + t·∫ßn su·∫•t
- [ ] **COMPLICATION_OF** - Tr√≠ch n·∫øu n√≥i bi·∫øn ch·ª©ng
- [ ] **REQUIRES_TEST** - Tr√≠ch n·∫øu n√≥i c·∫ßn ki·ªÉm tra
- [ ] **INCREASES_RISK** - Tr√≠ch n·∫øu n√≥i tƒÉng nguy c∆°
- [ ] **CONTRAINDICATED_WITH** - Tr√≠ch n·∫øu n√≥i tr√°nh d√πng c√πng
- [ ] **MANAGE_WITH** - Tr√≠ch n·∫øu n√≥i ƒëi·ªÅu tr·ªã k·∫øt h·ª£p
- [ ] **INTERACTION_WITH** - Tr√≠ch n·∫øu n√≥i t∆∞∆°ng t√°c h√≥a ch·∫•t
- [ ] **METABOLIZED_BY** - Tr√≠ch n·∫øu n√≥i chuy·ªÉn h√≥a enzyme
- [ ] **PREVENTS** - Tr√≠ch n·∫øu n√≥i ph√≤ng ng·ª´a
- [ ] **WORSENS** - Tr√≠ch n·∫øu n√≥i l√†m n·∫∑ng
- [ ] **ASSOCIATED_WITH** - Tr√≠ch n·∫øu n√≥i li√™n quan m∆° h·ªì
- [ ] **STAGES** - Tr√≠ch n·∫øu n√≥i giai ƒëo·∫°n b·ªánh
- [ ] **RISK_STRATIFICATION** - Tr√≠ch n·∫øu n√≥i ph√¢n t·∫ßng nguy c∆°

---

## üéØ K·∫øt lu·∫≠n

B·∫°n ƒë√£ n√¢ng c·∫•p t·ª´ **10 ‚Üí 20 lo·∫°i quan h·ªá**. ƒêi·ªÅu n√†y cho ph√©p:

‚úÖ Tr√≠ch xu·∫•t **chi ti·∫øt h∆°n** v·ªÅ t∆∞∆°ng t√°c thu·ªëc
‚úÖ H·ªó tr·ª£ **ki·∫øn th·ª©c y t·∫ø to√†n di·ªán** (ch·∫©n ƒëo√°n ‚Üí ƒëi·ªÅu tr·ªã ‚Üí gi√°m s√°t)
‚úÖ X√¢y d·ª±ng **ƒë·ªì th·ªã y t·∫ø chuy√™n s√¢u** cho y b√°c sƒ©
‚úÖ Ph√°t hi·ªán **contraindication & interactions** t·ª± ƒë·ªông

**ƒê·ªÅ xu·∫•t ti·∫øp theo**: C√≥ th·ªÉ th√™m c√°c quan h·ªá n·∫øu c·∫ßn:
- PALLIATIVE_CARE (chƒÉm s√≥c gi·∫£m nh·∫π)
- LIFESTYLE_MODIFICATION (thay ƒë·ªïi l·ªëi s·ªëng)
- SCREENING_FOR (s√†ng l·ªçc)
- ALTERNATIVE_TO (thay th·∫ø)
